Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Tirzepatide is a unimolecular co‐agonist of the glucagon‐like peptide‐1 (GLP‐1) and
glucose‐dependent insulinotropic polypeptide (GIP) receptors recently approved for the …

Geroscience posits that cardiovascular disease (CVD) and other chronic diseases result
from progressive erosion of the effectiveness of homeostatic mechanisms that oppose age …

Stroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular
complication has been less carefully investigated than the risk of cardiovascular mortality …

In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated
beneficial renoprotective effects, which culminated in the recent approval of their use for …

Type 2 diabetes mellitus (T2DM) is a risk factor for osteoporosis. The effects of T2DM and
anti-diabetic agents on bone and mineral metabolism have been observed. Sodium …

New hypoglycemic drugs, including glucagon-like peptide 1 receptor agonists (GLP-1RA),
dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter 2 inhibitors …

Objective To examine the association between dipeptidyl peptidase-4 inhibitors and
gallbladder or biliary diseases. Design Systematic review and pairwise and network meta …

Preconditioning, postconditioning, and remote conditioning of the myocardium enhance the
ability of the heart to withstand a prolonged ischemia/reperfusion insult and the potential to …

Background Currently, it remains uncertain whether metabolic dysfunction-associated fatty
liver disease (MAFLD) is associated with increased risk of supraventricular and ventricular …